[ THE JENEX CORPORATION ]











	If you would like to receive press releases and other company information, enter email address below.
	subscribe unsubscribe



	THE JENEX CORPORATION TO EXPLORE TECHNOLOGY ACQUISITION OPPORTUNITIES For Immediate Release April 23, 2004 THE JENEX CORPORATION (“Jenex” or the “Corporation”) (TSX Venture Exchange – JEN), Michael Jenkins, President and CEO of Jenex announces that 133,333 common shares of the Corporation will be issued at a deemed price of $0.30 per common share to Utek Corporation of Plant City, Florida as consideration to identify technology acquisition opportunities for The Jenex Corporation from research universities and government laboratories. The total value of the debt settlement is $40,000.00cdn. The proposed transaction is arms-length. The transaction is subject to TSX Venture Exchange approval and the shares will be subject to a four-month hold period from the date of issue. ABOUT THE JENEX CORPORATION The Corporation has proven that its patented technology is effective against HSV-1, the herpes virus that causes cold sores. In 2000, the Corporation received approval to make the following claim in Canada: “For prevention and relief of the symptoms of herpes labialis (cold sores), such as blistering, lesions, inflammation, and discomfort. Also helps alleviate the embarrassment that typically is associated with herpes labialis (cold sore) out breaks.” Between 20% and 40% of the population age twelve and over experience two or more cold sores per year. Jenex has the only product approved for the prevention of cold sores. “Prevention is the Solution” The TSX Venture Exchange Inc. has not reviewed and does not accept responsibility for the accuracy or the contents of this press release. Certain information included in this press release is forward-looking and is subject to important risks and uncertainties. The results or events predicted in these statements may differ materially from actual results or events. For more information please contact: The Jenex Corporation 207 – 940 Sheldon Court Burlington, Ontario L7L 5K6 Michael A. Jenkins, President Telephone: (905) 632-3830 Facsimile: (905) 632-3774 Email: jenex@sprint.ca www.jenexcorp.com .